SF-2626

N/A

Report date: 2023/05/22 10:19:11
NME

Base Information

Drug NameSF-2626
Drug Alias NameSF-2626
ClassificationSmall molecules
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase inhibitorsPI3-kinase class I inhibitors
TargetsDual specificity mitogen-activated protein kinase kinasePI3-kinase class I
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSignalrx Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSignalrx Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A